Harvard Bioscience (HBIO) Expected to Announce Quarterly Earnings on Thursday

Harvard Bioscience (NASDAQ:HBIO) will likely be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.0050 per share and revenue of $20.00 million for the quarter. Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Harvard Bioscience Trading Up 7.4%

Shares of Harvard Bioscience stock opened at $0.62 on Wednesday. Harvard Bioscience has a 12-month low of $0.28 and a 12-month high of $2.82. The stock has a market cap of $27.44 million, a PE ratio of -0.47 and a beta of 1.52. The company has a 50-day moving average of $0.46 and a two-hundred day moving average of $0.45.

Institutional Investors Weigh In On Harvard Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of HBIO. Jane Street Group LLC increased its position in shares of Harvard Bioscience by 491.9% in the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 58,785 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Harvard Bioscience in the 2nd quarter valued at about $61,000. Bank of America Corp DE boosted its holdings in shares of Harvard Bioscience by 44.4% in the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares during the period. Strs Ohio acquired a new position in shares of Harvard Bioscience in the 1st quarter valued at about $117,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after buying an additional 78,276 shares during the period. Institutional investors own 80.87% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HBIO. Wall Street Zen upgraded shares of Harvard Bioscience to a “buy” rating in a report on Saturday. Benchmark decreased their price target on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a report on Wednesday, September 10th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Harvard Bioscience in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $2.00.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.